Literature DB >> 27389080

Cerebral microbleeds in early Alzheimer's disease.

T Poliakova1,2, O Levin1, A Arablinskiy2, E Vasenina1, I Zerr3.   

Abstract

We hypothesize that cerebral microbleeds (CMB) in patients with different neuropsychological profiles (amnestic or non-amnestic) and MRI features of vascular damage could provide important information on the underlying pathological process in early Alzheimer's disease. The study was performed at two trial sites. We studied 136 outpatients with cognitive decline. MRI was performed using a magnetic field of 1.5 and 3 T. Neuropsychological assessment included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment scale (MoCA), Addenbrooke's Cognitive Examination (ACE-R), Cambridge Cognitive Examination battery (CAMCOG) (Part 3), Clock Drawing Test, fluency test and the visual memory test (SCT). CSF was examined for standard parameters such as tau, phosphorylated tau, amyloid-β 1-40 and 42 and Qalbumin, in accordance with established protocols and genotype. In 61 patients (45 %), at least 1 CMB was found. Most of the CMBs were described in the amnestic profile (67 %). In 86 % of the cases, multiple CMB were observed. The ratio of Aβ1-40/42 in non-amnestic patients with CMB was significantly lower (mean 0.6) than in patients without CMB (mean 1.2). A notable difference in the albumin ratio as an indicator of the BBB was observed between groups with and without CMB. In the CMP-positive group, the E2 genotype was observed more frequently, and the E4 genotype less frequently, than in the CMB-negative group. Based on the cerebrospinal fluid-serum albumin ratio, we were able to show that patients with CMB present several features of BBB dysfunction. According to logistic regression, the predictive factors for CMB in patients with cognitive decline were age, WMHs score and albumin ratio. We found a significant reduction in the Aβ-amyloid ratio in the non-amnestic profile group with CMB (particularly in the cortical region) in comparison to those without CMB. While this is an interesting finding, its significance needs to be assessed in a prospective follow-up.

Entities:  

Keywords:  Alzheimer disease; Blood–brain barrier damage; Cerebral microbleeds; Magnetic resonance imaging; Mild cognitive impairment; White matter lesions

Mesh:

Substances:

Year:  2016        PMID: 27389080     DOI: 10.1007/s00415-016-8220-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  38 in total

1.  Blood-brain barrier permeability abnormalities in vascular cognitive impairment.

Authors:  Saeid Taheri; Charles Gasparovic; Branko N Huisa; John C Adair; Elaine Edmonds; Jillian Prestopnik; Mark Grossetete; N Jon Shah; John Wills; Clifford Qualls; Gary A Rosenberg
Journal:  Stroke       Date:  2011-06-30       Impact factor: 7.914

2.  Blood brain barrier function in vascular dementia.

Authors:  A Wallin; K Blennow; P Fredman; C G Gottfries; I Karlsson; L Svennerholm
Journal:  Acta Neurol Scand       Date:  1990-04       Impact factor: 3.209

3.  A raging fire in acute lacunar stroke: inflammation, blood-brain barrier dysfunction and the origin of cerebral microbleeds.

Authors:  Andreas Charidimou; David J Werring
Journal:  J Neurol Sci       Date:  2014-03-11       Impact factor: 3.181

4.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Authors:  Peder Buchhave; Lennart Minthon; Henrik Zetterberg; Asa K Wallin; Kaj Blennow; Oskar Hansson
Journal:  Arch Gen Psychiatry       Date:  2012-01

Review 5.  Clinical associations of cerebral microbleeds on magnetic resonance neuroimaging.

Authors:  Matthew Schrag; David M Greer
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-10-05       Impact factor: 2.136

6.  Relationship between cerebral microbleeds and cognitive function in lacunar infarct.

Authors:  Min Zhang; Maogang Chen; Qizhang Wang; Wenwei Yun; Zhizhong Zhang; Qin Yin; Qinsong Huang; Wusheng Zhu
Journal:  J Int Med Res       Date:  2013-02-06       Impact factor: 1.671

7.  No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.

Authors:  Daniëlle M E van Assema; Jeroen D C Goos; Wiesje M van der Flier; Mark Lubberink; Ronald Boellaard; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-16       Impact factor: 6.200

8.  Investigating the association of ApoE genotypes with blood-brain barrier dysfunction measured by cerebrospinal fluid-serum albumin ratio in a cohort of patients with different types of dementia.

Authors:  André Karch; Henrike Manthey; Claudia Ponto; Peter Hermann; Uta Heinemann; Christian Schmidt; Inga Zerr
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

Review 9.  Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations.

Authors:  Paul A Yates; Victor L Villemagne; Kathryn A Ellis; Patricia M Desmond; Colin L Masters; Christopher C Rowe
Journal:  Front Neurol       Date:  2014-01-06       Impact factor: 4.003

10.  A meta-analysis of association between cerebral microbleeds and cognitive impairment.

Authors:  Rihan Wu; Chao Feng; Yanxin Zhao; Ai-Ping Jin; Min Fang; Xueyuan Liu
Journal:  Med Sci Monit       Date:  2014-11-07
View more
  18 in total

1.  In vivo imaging and analysis of cerebrovascular hemodynamic responses and tissue oxygenation in the mouse brain.

Authors:  Kassandra Kisler; Divna Lazic; Melanie D Sweeney; Shane Plunkett; Mirna El Khatib; Sergei A Vinogradov; David A Boas; Sava Sakadži; Berislav V Zlokovic
Journal:  Nat Protoc       Date:  2018-05-24       Impact factor: 13.491

2.  Blood-brain barrier link to human cognitive impairment and Alzheimer's Disease.

Authors:  Giuseppe Barisano; Axel Montagne; Kassandra Kisler; Julie A Schneider; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Nat Cardiovasc Res       Date:  2022-02-07

Review 3.  Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.

Authors:  Napatsorn Saiyasit; Evan-Angelo R Butlig; Samantha D Chaney; Miranda K Traylor; Nanako A Hawley; Ryleigh B Randall; Hanna V Bobinger; Carl A Frizell; Franklin Trimm; Errol D Crook; Mike Lin; Benjamin D Hill; Joshua L Keller; Amy R Nelson
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

Review 4.  GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.

Authors:  Giulia Monti; Diana Gomes Moreira; Mette Richner; Henricus Antonius Maria Mutsaers; Nelson Ferreira; Asad Jan
Journal:  Cells       Date:  2022-06-25       Impact factor: 7.666

Review 5.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

6.  Assessment of cerebral microbleeds by susceptibility-weighted imaging at 3T in patients with end-stage organ failure.

Authors:  Gianvincenzo Sparacia; Roberto Cannella; Vincenzina Lo Re; Angelo Gambino; Giuseppe Mamone; Roberto Miraglia
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

Review 7.  The role of brain vasculature in neurodegenerative disorders.

Authors:  Melanie D Sweeney; Kassandra Kisler; Axel Montagne; Arthur W Toga; Berislav V Zlokovic
Journal:  Nat Neurosci       Date:  2018-09-24       Impact factor: 24.884

Review 8.  Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.

Authors:  Amy R Nelson
Journal:  Front Aging Neurosci       Date:  2022-04-18       Impact factor: 5.702

Review 9.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

10.  Vascular dysfunction-The disregarded partner of Alzheimer's disease.

Authors:  Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Daniel A Nation; Lon S Schneider; Helena C Chui; Michael G Harrington; Judy Pa; Meng Law; Danny J J Wang; Russell E Jacobs; Fergus N Doubal; Joel Ramirez; Sandra E Black; Maiken Nedergaard; Helene Benveniste; Martin Dichgans; Costantino Iadecola; Seth Love; Philip M Bath; Hugh S Markus; Rustam Al-Shahi Salman; Stuart M Allan; Terence J Quinn; Rajesh N Kalaria; David J Werring; Roxana O Carare; Rhian M Touyz; Steve C R Williams; Michael A Moskowitz; Zvonimir S Katusic; Sarah E Lutz; Orly Lazarov; Richard D Minshall; Jalees Rehman; Thomas P Davis; Cheryl L Wellington; Hector M González; Chun Yuan; Samuel N Lockhart; Timothy M Hughes; Christopher L H Chen; Perminder Sachdev; John T O'Brien; Ingmar Skoog; Leonardo Pantoni; Deborah R Gustafson; Geert Jan Biessels; Anders Wallin; Eric E Smith; Vincent Mok; Adrian Wong; Peter Passmore; Frederick Barkof; Majon Muller; Monique M B Breteler; Gustavo C Román; Edith Hamel; Sudha Seshadri; Rebecca F Gottesman; Mark A van Buchem; Zoe Arvanitakis; Julie A Schneider; Lester R Drewes; Vladimir Hachinski; Caleb E Finch; Arthur W Toga; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Alzheimers Dement       Date:  2019-01       Impact factor: 16.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.